TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Optimizing Dietary Fatty Acids to Lower Metabolic Risk Factors Among Canadians

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Non-smoking, with BMI \> 19 \< 28 kg/m2~* Waist circumference \< 102 cm (40 in) for men and \< 88 cm (35 in) for women~* No known chronic disease such as diabetes, heart or thyroid disease or disorder of fat metabolism~* Not taking OTC or prescription medications, not following a vegan or vegetarian diet, not taking fish oil~* Willing to avoid some high fat foods and alcohol for two days, then eat a standardized meal with collection of blood samples over the following 8 hours~Exclusion Criteria:~* No elite athletes or those engaged in vigorous physical activity~* Smokers or those with BMI \> 28 or \<19~* Waist circumference \> 102 cm for men and 88 cm for women~* Known chronic disease such as diabetes or disease involving fat metabolism, the heart or thyroid will be excluded from the study~* Subjects who take any routine prescribed or over-the-counter medications, fatty acids, antioxidant or fish oil, those following a vegan or vegetarian diet, and those who are not willing to abstain from alcoholic beverages and high fat foods for 2 days prior to the test meal and not willing to eat a standardized meal and provide blood samples over the following 8 hours

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): In this study subjects will consume test meals containing vegetable oils (soy) and butter
- 2 (Type: ACTIVE_COMPARATOR): In this study subjects will consume test meals containing vegetable oils (flaxseed) and butter
- 3 (Type: ACTIVE_COMPARATOR): In this study subjects will consume test meals containing vegetable oils (high oleic safflower) and butter
- 4 (Type: ACTIVE_COMPARATOR): In this study subjects will consume test meals containing vegetable oils (canola) and butter

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: LARC Forward Contraceptive Counseling at MHCC

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* English or Spanish-speaking women.~* 17-30 years of age.~* Currently enrolled in a 2-year certificate program at Mount Hood Community College.~* At risk for pregnancy (sexually active with men or anticipate becoming sexually active in the next 6 months).~* Do not desire pregnancy within the next 12 months.~* No contraindications to LARC according to the Center for Disease Control and Prevention medical eligibility criteria (CDC MEC)~Exclusion Criteria:~* Women who are not currently sexually active with men and who do not anticipate becoming sexually active with a male partner in the next 6 months.~* Women who have had a tubal ligation or other sterilization procedure.~* Women who desire pregnancy within the next 12 months.~* Women currently already using a LARC method for contraception.

- Gender: FEMALE
- Minimum Age: 17 Years
- Maximum Age: 30 Years
- Healthy Volunteers: t

Study Arms:
- Non-LARC Group: Short Acting Method (Type: ACTIVE_COMPARATOR): All groups will receive the same standardized contraceptive counseling (LARC forward counseling). Participants who chose a short-acting hormonal method (e.g. contraceptive pills, ring, or patch) will receive a prescription to the pharmacy of their choice, as is the current practice for students who present for contraceptive services
- Control Group: Referral for LARC Placement (Type: ACTIVE_COMPARATOR): All groups will receive the same standardized contraceptive counseling (LARC forward counseling). Randomized to referral for LARC placement to local clinic.
- LARC Group: Same Day LARC Placement (Type: ACTIVE_COMPARATOR): All groups will receive the same standardized contraceptive counseling (LARC forward counseling). Randomized to same day LARC placement (intervention).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Udenafil Therapy to Improve Symptomatology, Exercise Tolerance and Hemodynamics in Patients With Chronic Systolic Heart Failure

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* ≥ 18 years of age, LV EF \< 40%~Exclusion Criteria:~* long-term use of medications that inhibit cytochrome P450 3A4.~* inability patients with exercise test~* primary pulmonary artery hypertension~* severe hypotension (\< 90/50mmHg) or severe hypertension (\> 170/100mmHg)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- placebo arm (Type: PLACEBO_COMPARATOR): Capsule that is identically appearing with udenafil will be administered to patients in placebo group. For the first 4 weeks, patients will receive 50 mg of placebo drug two times a day, and then the dosage will be doubled to 100 mg two times a day for next 8 weeks.
- Udenafil (Type: ACTIVE_COMPARATOR): Patients will receive 50 mg of udenafil two times a day, and then the dosage will be doubled to 100 mg two times a day for next 8 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: AngioSculpt Scoring Balloon Catheter For Bifurcation Coronary Lesions (ABC Study)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with significant (≥ 50% diameter stenosis) native coronary artery disease involving a bifurcation (Medina class (x,x,1)).~Exclusion Criteria:~* Concomitant use of Rotablator, Cutting Balloon, or investigational coronary devices.~* Additional planned coronary interventions for a non-target lesion within 30 days of the study procedure.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Single Arm - Interventional

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Memantine Therapy for Multiple Sclerosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with MS (McDonald 2002), both sex, age between 18 to 60 years old, all MS subtypes (RR, SP, PP, PR), stable.~* Patients with severe cognitive impairment defined as performing 1.5 SD below control group (matched by age and education) in 2 o more subtests based in our previous study (Sepulcre 2006):~Exclusion Criteria:~* Psychiatric diseases (Cummings) depression (Hamilton \>8), drug or alcohol abuse, benzodiazepine therapy or other medical diseases.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- A (Type: ACTIVE_COMPARATOR): Memantine 30 mg/day
- B (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: Drug to Prevent Pneumonia in the Tube Fed

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Tube fed for more than four weeks for reason of neurological dysphagia as recommended by a trained speech therapist;~* clinical diagnosis of cerebrovascular diseases, confirmed by CT head scan. The reason for restricting the subjects to those with cerebrovascular disease is that previous studies which showed beneficial effects of ACEI on dysphagia were mostly based on stroke patients.~Exclusion Criteria:~* life expectancy less than six months;~* live outside Shatin area;~* systolic blood pressure less than 100 mm Hg;~* known intolerance of ACEI;~* existing use of ACEI or angiotensin receptor blockers;~* symptomatic chronic lung disease or cardiac failure;~* frequent withdrawal of enteral tube by patients;~* serum creatinine \>100 µmol/L;~* serum potassium \> 5.1 mmol/L.

- Gender: ALL
- Minimum Age: 60 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Angiotensin converting enzyme inhibitor (Type: EXPERIMENTAL): Angiotensin converting enzyme inhibitor (Lisinopril), 2.5mg, nocte, 26 weeks
- Placebo (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Dexamethasone for Treatment of Radiation-related Fatigue in Patients Receiving RT for Head-neck and Lung Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* confirmation of head \& neck cancer (stage I-IV) or non-small cell lung cancer (stage II \& III)~* Undergoing treatment with either radiation alone or in combination with chemotherapy~* Normal cognition and willingness to complete fatigue and quality of life forms, patient observation form, and pill diary~Exclusion Criteria:~* Hypersensitivity to dexamethasone or corticosteroids or Equal sugar substitute~* Corticosteroid within the past 30 days prior to study enrollment for greater than one week duration~* Planned Stereotactic Body Radiation Therapy (SBRT)~* Active psychosis~* Current pregnancy~* Active peptic ulcer disease or evidence of gastrointestinal bleed~* Current active tuberculosis or systemic fungal infection~* Previous diagnosis of diabetes mellitus~* Acute febrile illness~* Known human immunodeficiency virus or acquired immunodeficiency syndrome~* Major surgery within two weeks of study enrollment of which the patient has not recovered~* Psychostimulant use in the past 30 days prior to registration~* History of phenylketonuria (PKU)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm 1 Placebo (Type: PLACEBO_COMPARATOR): Subjects receiving radiation therapy or radiation and chemotherapy randomly assigned to placebo bid for 14 days
- Arm 2 Dexamethasone (Type: ACTIVE_COMPARATOR): Subjects receiving radiation therapy or radiation and chemotherapy randomly assigned to dexamethasone 4 mg bid for 14 days

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: regulatory/approval
Please assess the completion status of the following clinical trial:

Trial Title: Cilostazol and Nimodipine Combined Therapy After Aneurysmal Subarachnoid Hemorrhage (aSAH)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 18 years of age or older~* Anterior circulation aneurysm~* Patients who have undergone surgical intervention~* Absence of rebleeding or new intracranial hemorrhage noted on post-intervention CT scan~* Consent for study participation~Exclusion Criteria:~* Non-aneurysmal subarachnoid hemorrhage~* Multiple ruptured aneurysms~* Patients with congestive heart failure~* Severe aneurysmal subarachnoid hemorrhage (Hunt Hess Grade V)~* Active pathological bleeding~* Allergy to cilostazol~* Positive pregnancy test~* Coagulopathy not caused by anti-coagulant use~* History of hemorrhagic complications (gastrointestinal bleeding, etc)~* Uncontrolled or severe comorbidity that would qualify as an absolute contraindication for cilostazol~* Patients requiring anticoagulant/antiplatelet treatment following intervention (e.g. stent-assisted coiling or flow-diverting stent obliteration of aneurysm)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 100 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Implement standard treatment regimen of 60 mg nimodipine every 4 hours for 21 days and the standard aneurysmal subarachnoid treatment pathway.
- Experimental (Type: EXPERIMENTAL): Administer 100 mg cilostazol, twice daily for 14 days. In addition, implement the standard treatment regimen of 60 mg nimodipine every 4 hours for 21 days, and the standard aneurysmal subarachnoid treatment pathway.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: The Effect of Combination Lumacaftor and Ivacaftor on Markers of Hyperglycemia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: SCREENING
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Age 18 years old or greater~2. Patients diagnosed with cystic fibrosis (CF), genotype homozygous Phe508del~3. Subject has been started on lumacaftor-ivacaftor for clinical reasons, with no contraindication for starting the drug\* \* Contraindications for taking drug include abnormal liver enzyme tests, renal dysfunction, pregnancy or nursing mothers~Exclusion Criteria~1. Does not have a HgbA1c within 1 year prior to starting medication.~2. Has not been on the combination therapy for at least 2 months

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Lumacaftor-ivacaftor (Type: EXPERIMENTAL): Subjects will be monitored for glycemic changes before and after starting lumacaftor-ivacaftor.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: The Application of Cultured Cornea Stem Cells in Patients Suffering From Corneal Stem Cell Insufficiency

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* unilateral limbus defect larger than 180 degrees~* repeated corneal epithelial ulcer, loss of visual acuity or neovascularization due to limbal stem cell insufficiency~* no improvement after medical intervention for more than 6 months~* the patient is willing to receive surgery and postoperative follow up~Exclusion Criteria:~* bilateral limbus defect~* limbal stem cell insufficiency does not induce repeated corneal epithelial ulcer, loss of visual acuity or neovascularization~* corneal neovascularization deeper than 1/2 depth of surface matrix~* peripheral surface matrix is less than 200um thick~* no corneal reflex was induced by fiber less than 5mm length measured by Cocet-Bonnet esthesiometer~* improvement under medication~* perisurgical follow up less than 6 months~* unable to be long term followed up postoperatively~* glaucoma patients underwent glaucoma surgery, under medication, IOP \> 21mmHg~* glaucoma patients underwent glaucoma surgery, under medication, IOP \< 21mmHg, optic disc depression \> 90%~* severe incomplete eyelid closure~* severe dye eye syndrome, Schirmer test 5 min \< 3 mm~* contralateral eye limbus tissue cannot be obtained, or unable to be cultured~* pregnant

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Patients suffering from unilateral limbal stem cell insufficiency. Remove the abnormal surface tissue on the lesion cornea, transplant the amniotic membrane with cultured limbal stem cells on the denuded cornea. Cover with contact lens after operation, and apply topical antibiotics and steroids.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Sympathetic Nervous System Modulation in Hypertension

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Essential hypertension with blood pressure less than 140/90 on either an ACE inhibitor or angiotensin receptor blocker~Exclusion Criteria:~* Known valvular heart disease of more than mild severity~* Known coronary artery disease defined by an angiographic coronary artery stenosis greater than or equal to 50% luminal diameter narrowing, acute or previous myocardial infarction, or previous coronary revascularization~* Known non-ischemic cardiomyopathy with left ventricular ejection fraction less than 50%~* Atrial fibrillation~* Current treatment with a β-adrenergic blocking drug or a calcium channel blocker~* Current treatment with a psychoactive or other drug known to alter 123I-MIBG uptake~* Participation in another research study within the prior 30 days~* A life-limiting disease process that is likely to preclude completion of study participation~* Pregnancy or breast feeding~* Inability or unwillingness to provide informed consent~* Baseline resting heart rate less than 65 beats per minute~* Diabetes~* Iodine allergy~* Unwilling to sign informed consent.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- metoprolol succinate (Type: EXPERIMENTAL): Subjects will undergo I-123 MIBG testing before and after sustained-release beta-adrenergic blockade.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: CyberKnife® for Hepatic Metastases From Colorectal Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Male or Female~* Hepatic metastases from histologically confirmed colorectal adenocarcinoma~* 3 hepatic lesions or less present~* Cumulative size of hepatic lesions between 1 and 10 cm~* Treatment determined by the liver/GI tumor board or equivalent organization at the participating site~* Metastatic disease not amenable to surgery as assessed by the panel (including a surgeon) or patient who refuses surgery~* Patient must be able to undergo contrast enhanced CT for planning~* Age \>= 18 years old~* Performance Status (ECOG) ≤ 2~* Minimum of 6 months between the initial diagnosis of the disease and the first hepatic metastasis~* Minimum of 4 weeks between prior chemotherapy or targeted therapy and the first CyberKnife session~* Total bilirubin ≤ 3 times the upper limit of normal, ASAT and ALAT ≤ 5 times the upper limit of normal~* Albumin \>= 36 g/L and lymphocytes \>= 700/mm3~* No contraindication to fiducials implantation, hemostasis problems shall be corrected before implantation~* Life expectancy \>= 3 months~* Patient affiliated with a health insurance system. Applicable for French patients only.~* Patient having signed the informed consent~Exclusion Criteria:~* Prior abdominal radiation therapy~* Any evidence of visible intra-hepatic bile duct dilatation on pre-treatment images~* Extrahepatic metastases~* Current evidence of ascitis~* Renal insufficiency (creatinine clearance \< 45 ml/min)~* Known allergy to gold~* Pregnant or lactating woman~* Prior history of other cancer except basocellular carcinoma and in situ cervix carcinoma~* Patient already enrolled in another therapeutic clinical trial~* Inability to comply with follow-up visits for geographical, social or psychological reasons

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- CyberKnife SBRT (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Manual Therapy to Improve Quality of Life and Decrease Pain in Subjects With Endometriosis

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: OTHER
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of endometriosis~* Experience either pain with menstruation or other pelvic pain~* Able to complete the questionnaires online~Exclusion Criteria:~* Currently pregnant~* Cancer diagnosis~* Prior chemotherapy or radiation treatment(s)~* Prior treatment at Clear Passage

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- Manual Physical Therapy, retrospective (Type: None): Endometriosis subjects treated at Clear Passage with follow up to assess changes in pain and overall health in a retrospective chart review.
- Control, prospective (Type: None): Endometriosis control subjects not treated at Clear Passage that complete two questionnaires, 30 days apart, to assess changes in their pain levels.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues